Marshall & Sullivan Inc. WA Has $4.33 Million Position in Becton, Dickinson and Company (NYSE:BDX)

Marshall & Sullivan Inc. WA increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.7% in the 4th quarter, HoldingsChannel reports. The firm owned 19,081 shares of the medical instruments supplier’s stock after acquiring an additional 318 shares during the period. Becton, Dickinson and Company makes up approximately 2.1% of Marshall & Sullivan Inc. WA’s holdings, making the stock its 27th largest holding. Marshall & Sullivan Inc. WA’s holdings in Becton, Dickinson and Company were worth $4,329,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Livelsberger Financial Advisory acquired a new stake in shares of Becton, Dickinson and Company in the 3rd quarter valued at about $26,000. Ashton Thomas Securities LLC bought a new position in Becton, Dickinson and Company in the third quarter worth approximately $33,000. Tompkins Financial Corp grew its stake in Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 46 shares during the period. Sound Income Strategies LLC raised its position in shares of Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 44 shares during the period. Finally, Abound Wealth Management lifted its holdings in shares of Becton, Dickinson and Company by 96.0% in the 2nd quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 96 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Up 1.4 %

Shares of BDX traded up $3.29 during trading hours on Monday, reaching $236.96. 1,389,459 shares of the stock traded hands, compared to its average volume of 1,808,102. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $248.42. The company has a market cap of $68.72 billion, a price-to-earnings ratio of 39.89, a PEG ratio of 1.64 and a beta of 0.39. The stock has a fifty day simple moving average of $226.91 and a 200 day simple moving average of $232.45. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping the consensus estimate of $3.77 by $0.04. The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The company’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same quarter last year, the firm earned $3.42 EPS. On average, equities analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th were given a dividend of $1.04 per share. The ex-dividend date was Monday, December 9th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a dividend yield of 1.76%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 70.03%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on BDX shares. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price target for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Finally, Evercore ISI raised their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $283.50.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 2,838 shares of the business’s stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $223.33, for a total value of $633,810.54. Following the sale, the executive vice president now directly owns 6,141 shares in the company, valued at $1,371,469.53. The trade was a 31.61 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Shana Carol Neal sold 788 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total value of $185,180.00. Following the transaction, the executive vice president now owns 16,201 shares of the company’s stock, valued at $3,807,235. The trade was a 4.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 8,747 shares of company stock worth $1,949,520 in the last ninety days. Company insiders own 0.36% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.